CompletedNCT02138253POLT-HCV-SVRUpdated Dec 11, 2019Results posted

A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV

A Phase 2 interventional study of IDN-6556 and Placebo in Liver Fibrosis, Hepatic Fibrosis and Liver Cirrhosis, sponsored by Conatus Pharmaceuticals Inc.. Completed at 35 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-11.

Sponsored by Conatus Pharmaceuticals Inc. · Phase 2, Interventional, and Treatment

Phase: Phase 2
Study type: Interventional
Enrollment: 64
Allocation: Randomized
Ages: 18 Years and older
Sex: All

Study summary

This is a double-blind, multicenter study involving patients with chronic HCV infection who had a liver transplantation; developed HCV-related liver fibrosis and/or incomplete cirrhosis; achieved a sustained virologic response (SVR) following anti-HCV therapy; but still have fibrosis and/or incomplete cirrhosis on liver biopsy to see if treatment with IDN-6556 is better than placebo in reversing or stopping the progression of the damage to the new liver caused by HCV.

Read the detailed description

There are data to suggest that with eradication of the HCV virus, improvements in liver fibrosis can be seen in the post-transplant population. However, amelioration of inflammatory activity, and deceleration of fibrosis progression is a gradual process over the course of many years. This placebo-controlled study is designed to evaluate the effects of IDN-6556, compared to placebo, on markers of apoptosis and inflammation, and liver histology.

Conditions studied

Liver Fibrosis
Hepatic Fibrosis
Liver Cirrhosis
Hepatic Cirrhosis

Browse trials for

Keywords

liver transplant
hepatitis C
liver fibrosis
hepatic fibrosis
liver cirrhosis
hepatic cirrhosis

In context

Liver Cirrhosis

1,668 studies on the registry are indexed under Liver Cirrhosis; 360 are open to participants now.

This study's enrollment of 64 is below the median of 72 across 1,003 interventional studies indexed under Liver Cirrhosis.

Browse Liver Cirrhosis studies →

Lead sponsor

Conatus Pharmaceuticals Inc. is the lead sponsor of 17 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years and older
Sexes eligible: All
Accepts healthy volunteers: No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Male or female subjects of minimum adult legal age (according to local laws for signing the informed consent document), able to provide written informed consent, and able to understand and willing to comply with the requirements of the study
History of orthotopic liver transplantation for HCV-induced liver disease
Diagnosis of HCV infection (HCV-RNA detectable in serum) and liver fibrosis and/or incomplete cirrhosis status post liver transplantation, and achieved a sustained virologic response (SVR) with anti-viral HCV treatment within 18 months of Day 1
Liver fibrosis on liver histology as read by central histopathologist of Ishak F2 to F6 within three months of Day 1 (Up to 15 subjects with an Ishak score of F6 can be enrolled)
Willingness to utilize two reliable forms of contraception (for both males and females of childbearing potential) from Screening to one month after the last dose of study drug

Exclusion criteria

Exclusion Criteria:

Known infection with hepatitis B virus (HBV) and/or human immunodeficiency virus (HIV)
History of renal transplant and/or severe renal impairment defined as eGFR (estimated glomerular filtration rate) of less than 30 mL/min/1.73 m2
Evidence of tumor burden >Milan criteria, or evidence of micro- or macrovascular invasion in explanted liver
Hepatocellular carcinoma (HCC) at entry into the study
Concurrent sirolimus (rapamycin) use
History or presence of clinically concerning cardiac arrhythmias, or prolongation of Screening (pre-treatment) QT or QTc interval of > 480 milliseconds (msec)
Subjects with diagnosed or suspected systemic lupus erythematosus (SLE) and/or rheumatoid arthritis (RA)
If female: known pregnancy, positive urine or serum pregnancy test, or lactating/breastfeeding

Study design

Phase: Phase 2
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel assignment
Masking: Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment: 64 participants (actual)

Study arms

Experimental
IDN-6556
IDN-6556 25 mg BID
Drug: IDN-6556
Placebo comparator
Placebo
Placebo BID
Drug: Placebo

Interventions

DrugIDN-6556
Also known as: emricasan, PF-03491390
DrugPlacebo
Placebo control

What researchers measure

Primary outcomes

Number of Participants With At Least a One Stage Reduction From Baseline in Ishak Fibrosis Score
At least a one stage reduction from baseline in Ishak Fibrosis Stage. Score F0 No fibrosis F1 Fibrous expansion of some portal areas, with or without short fibrous septa F2 Fibrous expansion of most portal areas, with or without short fibrous septa F3 Fibrous expansion of most portal areas, with occasional portal to portal bridging F4 Fibrous expansion of portal areas, with marked bridging (portal to portal as well as portal to central) F5 Marked bridging (portal to portal and/or portal to central) with occasional nodules (incomplete cirrhosis) F6 Cirrhosis probable or definite Since the primary analysis used multiple imputation methodology, the numerator and denominator varied across 20 imputations.
Time frame: 24 months

Secondary outcomes

Number of Participants With At Least a One Stage Reduction From Baseline in Ishak Fibrosis Score (Observed Cases Only)
At least a one stage reduction from baseline in Ishak Fibrosis Stage. Score F0 No fibrosis F1 Fibrous expansion of some portal areas, with or without short fibrous septa F2 Fibrous expansion of most portal areas, with or without short fibrous septa F3 Fibrous expansion of most portal areas, with occasional portal to portal bridging F4 Fibrous expansion of portal areas, with marked bridging (portal to portal as well as portal to central) F5 Marked bridging (portal to portal and/or portal to central) with occasional nodules (incomplete cirrhosis) F6 Cirrhosis probable or definite
Time frame: 24 months
Number of Participants With At Least a One Stage Reduction From Baseline in Ishak Fibrosis Score
At least a one stage reduction from baseline in Ishak Fibrosis Stage. Score F0 No fibrosis F1 Fibrous expansion of some portal areas, with or without short fibrous septa F2 Fibrous expansion of most portal areas, with or without short fibrous septa F3 Fibrous expansion of most portal areas, with occasional portal to portal bridging F4 Fibrous expansion of portal areas, with marked bridging (portal to portal as well as portal to central) F5 Marked bridging (portal to portal and/or portal to central) with occasional nodules (incomplete cirrhosis) F6 Cirrhosis probable or definite
Time frame: 12 months
Alanine Aminotransferase (ALT) - Change From Baseline
Liver function laboratory parameter
Time frame: Baseline and 24 months
Aspartate Aminotransferase (AST) Change From Baseline
Liver function laboratory parameter
Time frame: Baseline and 24 months
Caspase 3/7 Change From Baseline
Mechanistic biomarker of liver function
Time frame: Baseline and 24 months
cCK18/M30 Change From Baseline
Mechanistic biomarker of liver function.
Time frame: Baseline and 24 months
flCK18/M65 Change From Baseline
Mechanistic biomarker of liver function
Time frame: Baseline and 24 months
Ishak Modification of Knodell Histological Activity Index - Interface Hepatitis
The Ishak modification of Knodell histological activity index was determined by liver biopsy. Interface hepatitis * 0 = None * 1 = Mild (local, few portal areas) * 2 = Mild/moderate (focal, most portal areas) * 3 = Moderate (continuous around \<50% of tracts or septa) * 4 = Severe (continuous around \>50% of tracts or septa)
Time frame: 24 months
Ishak Modification of Knodell Histological Index - Confluent Necrosis
The Ishak modification of Knodell histological activity index will be determined by liver biopsy. The four items and their categorizations scores include: • confluent necrosis * 0 = None * 1 = Focal confluent necrosis * 2 = Zone 3 necrosis in some areas * 3 = Zone 3 necrosis in most areas * 4 = Zone 3 necrosis + occasional portal-central bridging * 5 = Zone 3 necrosis + multiple portal-central bridging * 6 = Panacinar or multiacinar necrosis
Time frame: 24 months
Ishak Modification of Knodell Histological Index - Parenchymal Injury
The Ishak modification of Knodell histological activity index will be determined by liver biopsy. • parenchymal injury (focal lytic necrosis, apoptosis and focal inflammation) * 0 = None * 1 = One focus or less per 10× objective * 2 = Two to four foci per 10× objective * 3 = Five to ten foci per 10× objective * 4 = More than ten foci per 10× objective
Time frame: 24 months
Ishak Modification of Knodell Histological Index - Portal Inflammation
Portal inflammation * 0 = None * 1 = Mild, some or all portal areas * 2 = Moderate, some or all portal areas * 3 = Moderate/marked, all portal areas * 4 = Marked, all portal areas
Time frame: 24 months

Results

Posted Dec 11, 2019

Limitations and caveats

The broad range of fibrosis stages included in the study and the high placebo response rates especially in the F2 and F6 fibrosis stages impacted the primary endpoint of improvement in fibrosis score from baseline.

Participant flow

Subjects were enrolled from 20 of 35 US sites that obtained IRB approval. First subject randomized Sep 2014, last subject last visit was 15 Feb 2018. A total of 114 subjects were screened, 64 subjects randomized with 41 subjects randomized to emricasan and 23 subjects randomized to placebo. Thirteen subjects discontinued the study.

Participant flow — Overall Study
Milestone	IDN-6556	Placebo
Started	41	23
Completed	32	19
Not completed	9	4
Withdrew: Adverse event	3	3
Withdrew: Lost to follow-up	2	1
Withdrew: Physician decision	2	0
Withdrew: Non compliance	1	0
Withdrew: Withdrawal by subject	1	0

Outcome measures

PrimaryNumber of Participants With At Least a One Stage Reduction From Baseline in Ishak Fibrosis Score

At least a one stage reduction from baseline in Ishak Fibrosis Stage. Score F0 No fibrosis F1 Fibrous expansion of some portal areas, with or without short fibrous septa F2 Fibrous expansion of most portal areas, with or without short fibrous septa F3 Fibrous expansion of most portal areas, with occasional portal to portal bridging F4 Fibrous expansion of portal areas, with marked bridging (portal to portal as well as portal to central) F5 Marked bridging (portal to portal and/or portal to central) with occasional nodules (incomplete cirrhosis) F6 Cirrhosis probable or definite Since the primary analysis used multiple imputation methodology, the numerator and denominator varied across 20 imputations.

Time frame:: 24 months
Reported as:: Number · participants

Number of Participants With At Least a One Stage Reduction From Baseline in Ishak Fibrosis Score
participants	IDN-6556	Placebo
Number of Participants With At Least a One Stage Reduction From Baseline in Ishak Fibrosis Score	25	14

Statistical analysis

IDN-6556 vs Placebo · Cochran-Mantel-Haenszel · p = 0.73 (Stratified by baseline Ishak Fibrosis Score strata (F2, F3+F4+F5, and F6).) · Risk difference (rd): 2.9 · 95% CI -20.5 to 26.4

SecondaryNumber of Participants With At Least a One Stage Reduction From Baseline in Ishak Fibrosis Score (Observed Cases Only)

Time frame:: 24 months
Reported as:: Count of participants · Participants

Number of Participants With At Least a One Stage Reduction From Baseline in Ishak Fibrosis Score (Observed Cases Only)
Participants	IDN-6556	Placebo
Number of Participants With At Least a One Stage Reduction From Baseline in Ishak Fibrosis Score (Observed Cases Only)	25	14

Statistical analysis

IDN-6556 vs Placebo · Cochran-Mantel-Haenszel · p = 0.658 · Risk difference (rd): 4.4 · 95% CI -20.0 to 28.9

SecondaryNumber of Participants With At Least a One Stage Reduction From Baseline in Ishak Fibrosis Score

Time frame:: 12 months
Reported as:: Count of participants · Participants

Number of Participants With At Least a One Stage Reduction From Baseline in Ishak Fibrosis Score
Participants	IDN-6556	Placebo
Number of Participants With At Least a One Stage Reduction From Baseline in Ishak Fibrosis Score	27	17

Statistical analysis

IDN-6556 vs Placebo · Cochran-Mantel-Haenszel · p = 0.421 · Risk difference (rd): -7.9 · 95% CI -28.8 to 13.1

SecondaryAlanine Aminotransferase (ALT) - Change From Baseline

Liver function laboratory parameter

Time frame:: Baseline and 24 months
Reported as:: Mean · U/L

Alanine Aminotransferase (ALT) - Change From Baseline
U/L	IDN-6556	Placebo
Alanine Aminotransferase (ALT) - Change From Baseline	-3.7 ± 10	43.7 ± 239.5

SecondaryAspartate Aminotransferase (AST) Change From Baseline

Liver function laboratory parameter

Time frame:: Baseline and 24 months
Reported as:: Mean · U/L

Aspartate Aminotransferase (AST) Change From Baseline
U/L	IDN-6556	Placebo
Aspartate Aminotransferase (AST) Change From Baseline	-4.0 ± 8.5	31.4 ± 161.8

SecondaryCaspase 3/7 Change From Baseline

Mechanistic biomarker of liver function

Time frame:: Baseline and 24 months
Reported as:: Mean · Raw RLU

Caspase 3/7 Change From Baseline
Raw RLU	IDN-6556	Placebo
Caspase 3/7 Change From Baseline	-296.1 ± 830.3	2081.2 ± 10116.4

SecondarycCK18/M30 Change From Baseline

Mechanistic biomarker of liver function.

Time frame:: Baseline and 24 months
Reported as:: Mean · U/L

cCK18/M30 Change From Baseline
U/L	IDN-6556	Placebo
cCK18/M30 Change From Baseline	-104.7 ± 193.2	-66.1 ± 176.9

SecondaryflCK18/M65 Change From Baseline

Mechanistic biomarker of liver function

Time frame:: Baseline and 24 months
Reported as:: Mean · U/L

flCK18/M65 Change From Baseline
U/L	IDN-6556	Placebo
flCK18/M65 Change From Baseline	-70.2 ± 189.0	-98.6 ± 311.7

SecondaryIshak Modification of Knodell Histological Activity Index - Interface Hepatitis

The Ishak modification of Knodell histological activity index was determined by liver biopsy. Interface hepatitis * 0 = None * 1 = Mild (local, few portal areas) * 2 = Mild/moderate (focal, most portal areas) * 3 = Moderate (continuous around \<50% of tracts or septa) * 4 = Severe (continuous around \>50% of tracts or septa)

Time frame:: 24 months
Reported as:: Count of participants · Participants

Ishak Modification of Knodell Histological Activity Index - Interface Hepatitis
Participants	IDN-6556	Placebo
Interface Hepatitis Score of 0	6	5
Interface Hepatitis Score of 1	14	4
Interface Hepatitis Score of 2	8	6
Interface Hepatitis Score of 3	3	1
Interface Hepatitis Score of 4	1	3
Missing Interface Hepatitis Score	9	4

SecondaryIshak Modification of Knodell Histological Index - Confluent Necrosis

The Ishak modification of Knodell histological activity index will be determined by liver biopsy. The four items and their categorizations scores include: • confluent necrosis * 0 = None * 1 = Focal confluent necrosis * 2 = Zone 3 necrosis in some areas * 3 = Zone 3 necrosis in most areas * 4 = Zone 3 necrosis + occasional portal-central bridging * 5 = Zone 3 necrosis + multiple portal-central bridging * 6 = Panacinar or multiacinar necrosis

Time frame:: 24 months
Reported as:: Count of participants · Participants

Ishak Modification of Knodell Histological Index - Confluent Necrosis
Participants	IDN-6556	Placebo
Confluent necrosis score of 0	32	19
Missing confluent necrosis score	9	4

SecondaryIshak Modification of Knodell Histological Index - Parenchymal Injury

The Ishak modification of Knodell histological activity index will be determined by liver biopsy. • parenchymal injury (focal lytic necrosis, apoptosis and focal inflammation) * 0 = None * 1 = One focus or less per 10× objective * 2 = Two to four foci per 10× objective * 3 = Five to ten foci per 10× objective * 4 = More than ten foci per 10× objective

Time frame:: 24 months
Reported as:: Count of participants · Participants

Ishak Modification of Knodell Histological Index - Parenchymal Injury
Participants	IDN-6556	Placebo
Parenchymal Injury Score of 0	1	2
Parenchymal Injury Score of 1	22	9
Parenchymal Injury Score of 2	5	7
Parenchymal Injury Score of 3	4	1
Missing Parenchymal Injury Score	9	4

SecondaryIshak Modification of Knodell Histological Index - Portal Inflammation

Portal inflammation * 0 = None * 1 = Mild, some or all portal areas * 2 = Moderate, some or all portal areas * 3 = Moderate/marked, all portal areas * 4 = Marked, all portal areas

Time frame:: 24 months
Reported as:: Count of participants · Participants

Ishak Modification of Knodell Histological Index - Portal Inflammation
Participants	IDN-6556	Placebo
Portal Inflammation Score of 1	11	4
Portal Inflammation Score of 2	19	8
Portal Inflammation Score of 3	2	6
Portal Inflammation Score of 4	0	1
Missing Portal Inflammation Score	9	4

Adverse events

Collected over Treatment emergent adverse events were collected from the first day of study drug administration until the subject's last study follow-up visit. All treatment emergent adverse events were collected up to the subsequent follow-up visit of the month 24 month visit.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
Group	Deaths	Serious	Other
IDN-6556	0/41 (0%)	0/41 (0%)	37/41 (90.2%)
Placebo	1/23 (4.3%)	1/23 (4.3%)	20/23 (87%)

Most frequent serious events

Most frequent serious events
Event	IDN-6556	Placebo
DeathNeoplasms benign, malignant and unspecified (incl cysts and polyps)	0/41	1/23

Most frequent other events

Most frequent other events
Event	IDN-6556	Placebo
FatigueGeneral disorders	8/41	6/23
DiarrheaGastrointestinal disorders	9/41	5/23
NauseaGastrointestinal disorders	7/41	5/23
HypertensionVascular disorders	6/41	4/23
ArthralgiaMusculoskeletal and connective tissue disorders	6/41	2/23
Abdominal painGastrointestinal disorders	4/41	2/23

Baseline characteristics

Subjects who underwent orthotopic liver transplantation for chronic HCV, developed HCV-related liver fibrosis or cirrhosis, achieved a SVR with anti-viral treatment and had demonstrable fibrosis or cirrhosis on liver histology were enrolled.

Age, Categorical
Age, Categorical(Participants)	IDN-6556	Placebo	Total
<=18 years	0	0	0
Between 18 and 65 years	29	17	46
>=65 years	12	6	18

Sex: Female, Male
Sex: Female, Male(Participants)	IDN-6556	Placebo	Total
Female	9	5	14
Male	32	18	50

Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)	IDN-6556	Placebo	Total
Hispanic or Latino	10	6	16
Not Hispanic or Latino	31	17	48
Unknown or Not Reported	0	0	0

Race (NIH/OMB)
Race (NIH/OMB)(Participants)	IDN-6556	Placebo	Total
American Indian or Alaska Native	0	0	0
Asian	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	7	2	9
White	30	20	50
More than one race	1	0	1
Unknown or Not Reported	3	1	4

Region of Enrollment
Region of Enrollment(participants)	IDN-6556	Placebo	Total
United States	41	23	64

Baseline Ishak Fibrosis Score
Baseline Ishak Fibrosis Score(participants)	IDN-6556	Placebo	Total
Baseline Ishak Fibrosis Score F2	9	6	15
Baseline Ishak Fibrosis Score F3	20	7	27
Baseline Ishak Fibrosis Score F4	5	5	10
Baseline Ishak Fibrosis Score F5	2	2	4
Baseline Ishak Fibrosis Score F6	5	3	8

Study locations

35 sites

Southern California Research Center
Coronado, California 92118, United States
Scripps Clinic
La Jolla, California 92037, United States
Loma Linda University Medical Center
Loma Linda, California 92354, United States
UCLA Pfleger Liver Institute
Los Angeles, California 90095, United States
Georgetown University Hospital
Washington D.C., District of Columbia 20007, United States
Johns Hopkins Sibley Memorial Hospital
Washington D.C., District of Columbia 21287, United States
University of Florida
Gainesville, Florida 32610, United States
University of Miami
Miami, Florida 33136, United States
Piedmont Atlanta Hospital
Atlanta, Georgia 30309, United States
Rush University Medical Center
Chicago, Illinois 60612, United States
University of Chicago Medicine
Chicago, Illinois 60637, United States
Indiana University
Indianapolis, Indiana 46202, United States
University of Kansas Medical Center
Kansas City, Kansas 66160, United States
University of Louisville
Louisville, Kentucky 40202, United States
Tulane Health Science Center
New Orleans, Louisiana 70112, United States
Ochsner Clinic
New Orleans, Louisiana 70121, United States
John Hopkins Hospital
Baltimore, Maryland 21287, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts 02215, United States
Henery Ford Health System
Detroit, Michigan 48202, United States
Saint Louis University
St Louis, Missouri 63104, United States
Rutgers New Jersey Medical School
Newark, New Jersey 07103, United States
Columbia University Medical Center
New York, New York 10032, United States
University of Cincinnati Physicians Company
Cincinnati, Ohio 45267, United States
University of Pennsylvania Milton Hershey Hospital
Philadelphia, Pennsylvania 19104, United States
Temple University Hospital
Philadelphia, Pennsylvania 19140, United States
Albert Einstein Medical Center
Philadelphia, Pennsylvania 19141, United States
Baylor All Saints Medical Center
Fort Worth, Texas 76104, United States
Liver Associates of Texas, PA
Houston, Texas 77030, United States
University of Texas Health Science Center at Houston
Houston, Texas 77030, United States
VAMC/Baylor College of Medicine
Houston, Texas 77030, United States
University of Utah
Salt Lake City, Utah 84132, United States
Bon Secours Mary Immaculate Hospital
Newport News, Virginia 23602, United States
Bon Secours St. Mary's Hospital of Richmond
Richmond, Virginia 23226, United States
McGuire DVAMC
Richmond, Virginia 23249, United States
University of Washington Harborview Medical Center
Seattle, Washington 98104, United States

References and documents

Study documents

Study protocol · Aug 3, 2015
Statistical analysis plan · Jan 18, 2018

Documents are hosted by the registry — open the source record to download them.

Timeline

Tracking since Sep 25, 2026

Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2014, a primary completion of Feb 2018 and a completion of Mar 2018. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2019, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered: May 12, 2014
First posted: May 14, 2014
Start: May 2014
Primary completionActual: Feb 15, 2018
CompletionActual: Mar 9, 2018
Results first posted: Dec 11, 2019
Last update: Dec 11, 2019

What these dates mean

Start.: When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.: When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.: When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.: Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.

No changes since tracking began. The registry record was last updated on Dec 11, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT02138253
Lead sponsor: Conatus Pharmaceuticals Inc.
Responsible party: Sponsor
First posted: May 14, 2014
Start date: May 2014
Primary completion: Feb 15, 2018
Completion: Mar 9, 2018
Results posted: Dec 11, 2019
Last update: Dec 11, 2019

Study contacts

David Hagerty, MD

study chair · Conatus Pharmaceuticals Inc.

Oversight

Data monitoring committee: Yes

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Emricasan

Other studies in this condition

Liver Cirrhosis →

Other studies from this sponsor

Conatus Pharmaceuticals Inc.

Start the discussion

A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV

Study summary

Conditions studied

Browse trials for

Keywords

In context

Liver Cirrhosis

Lead sponsor

Who can participate

✓Inclusion criteria

✕Exclusion criteria

Study design

Study arms

Interventions

What researchers measure

Primary outcomes

Secondary outcomes

Results

Participant flow

Outcome measures

Adverse events

Baseline characteristics

Study locations

References and documents

Study documents

Timeline

Registry details

Key details

Study contacts

Oversight

Not currently enrolling

Follow this study

Discussion

Other studies in this condition

Other studies from this sponsor

Inclusion criteria

Exclusion criteria